Related Experiment Videos
[Erythropoietin treatment of dialysis patients]
1Nefrologisk afdeling, Hvidovre Hospital, København.
The effect of recombinant human erythropoietin therapy on correction of renal anaemia was evaluated. A total of 100 patients with endstage renal disease and anaemia (level of haemoglobin < 9.6 g/dl) received erythropoietin for 125 patient years. In 81 patients the level of haemoglobin increased to the intended range (10.5-12.0 g/dl) within three to four months. In 16 of the patients acute infections were followed by a temporary reduction in the haemoglobin level. In 11 patients a previous transfusion requirement was reduced, or, in most cases, abolished. In the remaining eight patients the transfusion requirement was unchanged. The patients with either a sub-optimal or no response suffered from chronic infections, malignant diseases or recurrent bleeding episodes. In 28 patients the level of haemoglobin exceeded the intended target for a period of four months (average). Serious side effects were not observed. Six patients had 'flu-like symptoms after the first injections. Three cases of thrombosis of the arterio-venous fistula were observed in two patients. The frequency of thrombosis of the vascular access did not exceed what we expected to find.
The effect of recombinant human erythropoietin therapy on correction of renal anaemia was evaluated. A total of 100 patients with endstage renal disease and anaemia (level of haemoglobin < 9.6 g/dl) received erythropoietin for 125 patient years. In 81 patients the level of haemoglobin increased to the intended range (10.5-12.0 g/dl) within three to four months. In 16 of the patients acute infections were followed by a temporary reduction in the haemoglobin level. In 11 patients a previous transfusion requirement was reduced, or, in most cases, abolished. In the remaining eight patients the transfusion requirement was unchanged. The patients with either a sub-optimal or no response suffered from chronic infections, malignant diseases or recurrent bleeding episodes. In 28 patients the level of haemoglobin exceeded the intended target for a period of four months (average). Serious side effects were not observed. Six patients had 'flu-like symptoms after the first injections. Three cases of thrombosis of the arterio-venous fistula were observed in two patients. The frequency of thrombosis of the vascular access did not exceed what we expected to find.